Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PTO snagged in court

PTO snagged in court

PTO snagged in court
GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) last week won the first round in its suit seeking to permanently enjoin the U.S. Patent & Trademark Office from a new final rule that would limit the number of continuing applications, requests for continued examination (RCE) and claims allowed for patent applications. The rule was published in August and had been scheduled to take effect Nov. 1. IP specialists had warned the rule would prevent biopharma companies from protecting all the aspects of their inventions, and risk having subsequent improvements eclipsed by prior art (see BioCentury, Aug. 27).
Judge James Cacheris

Read the full 1062 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers